Leading Aesthetic Innovation Company Appoints Veteran Industry Experts Derek Harmon as Vice President of U.S. Sales and Don Selvey, NMD, MS as Vice President of Regulatory
PHOENIX, July 27, 2022 /PRNewswire-PRWeb/ -- Aesthetics Biomedical® Inc. (ABM), in its ongoing efforts to meet the increasing demand for its revolutionary aesthetic products and distribution growth, is continuing to build its executive team recruiting top industry experts Derek Harmon as Vice President of U.S. Sales and Don Selvey, NMD, MS as Vice President of Regulatory respectively. Mr. Harmon and Dr. Selvey will play pivotal roles in the company's expansion and national distribution of current products including the legacy Vivace® Microneedle RF treatment and device, SoME® PRP Skincare and focus on the new era of energy-based technology with Vivace Ultra™, with expected FDA Clearance, is expected to roll-out via limited commercial release in the fall to top tier plastic surgeons, dermatologists, and medical aesthetic practitioners across the country.
"I'm honored to be joining an organization about to reignite aesthetics with Vivace Ultra™ and SoME® PRP Skincare," says Derek Harmon. "I'm impressed with what the team has created that uniquely positions ABM as a leader in this industry", he continued. "After over two decades of experience encompassing a deep understanding of the aesthetics market and the needs of patients and providers alike, I could not be more thrilled to lead U.S. Sales, Practice Development, and Clinical teams to new heights with our portfolio."
Mr. Harmon brings an award-winning, 20+ year career of industry expertise, results, and leadership to the ABM Executive Team. A seasoned, results-oriented Sales & Marketing Executive with a background focused on aesthetics, medical devices, capital equipment, pharmaceutical and healthcare, Derek most recently served as Director of Surgical Sales at Cynosure. He co-created their surgical division and implemented MyEllevate®, their successful, minimally invasive surgical technology. Prior to Cynosure, Derek was the Director of Business Development for Fresenius Medical Care and responsible for the growth of $400M in treatment revenue, through strategic M&A, joint ventures, and real-estate development of clinics. Derek simultaneously led the company's telemedicine rollout during the COVID-19 pandemic to keep physicians, clinical teams, and patients safe during an unprecedented time.
Previously, he also spent nearly a decade at Allergan, holding various leadership roles in sales, marketing and practice development, building aesthetic markets for Botox® Cosmetic, Juvederm® XC, Kybella®, Voluma®, Latisse®, and the Allē℠ Patient Loyalty Program. Derek also held positions at Pfizer-Wyeth and Merck & Co. Inc. He currently serves as a Board Member for RealSelf's Industry Insiders.
Dr. Don Selvey will oversee Regulatory Affairs and Quality Assurance for Aesthetics Biomedical® Inc., bringing a combination of more than 30 years of clinical practice and industry experience in regulatory and clinical activity with medical device and pharmaceutical companies. Dr. Selvey has worked with medical device designers and manufacturers to produce novel devices such as external and implantable drug delivery systems, the original continuous glucose monitoring system, permanently implanted biomaterials for both bone and soft tissues, orthopedic implants and aesthetic dermal fillers and neuromodulators.
"I am very pleased to have joined Aesthetics Biomedical® Inc. working across compliance, quality and regulatory affairs departments for such an exceptional portfolio of advanced devices. With such a strong leadership team, innovative technologies in their Microneedle RadioFrequency device and breadth of practice relationships, I am excited for this next chapter with a company poised for even greater accomplishments and successes ahead.," says Dr. Selvey.
Aesthetics Biomedical®, led by Founder & Chief Executive Officer, MaryAnn Guerra, achieved its initial success with Vivace® Microneedle RF and Vivace Experience® in the US, the most well-known RF microneedling treatment device in the industry, with exceptional technology and patient outcome. Aesthetics Biomedical® is now poised for industry leadership in the advanced aesthetics space with an expanded, elevated and forward-thinking management team and the latest unique multi-modality device to deliver the most advances in bespoke aesthetics and beauty.
ABOUT AESTHETICS BIOMEDICAL®: Aesthetics Biomedical® Inc., headquartered in Phoenix, Ariz., is committed to the development and distribution of novel aesthetic devices, products, and services in the global market. Aesthetics Biomedical's innovation center is a leader in breakthrough technologies and combination therapies for its clients, physician network and the aesthetic arena, creating novel patient treatment experiences that benefit from ongoing research, approved clinical indications for use, as well as a personalized approach designed for consumer benefit. For more information, please visit AestheticsBiomedical.com. IG Twitter Linkedin Facebook
Media Contact
Jill Eisenstadt Chayet, Aesthetics Biomedical, 1 3106502900, [email protected]
SOURCE Aesthetics Biomedical
Share this article